cold & lip sore
Market research shows that the global market of $1.29bn is growing with a compounded annual rate of 6.1%. Our patented ingredient is driving category growth in Germany, branded as Lyranda® since its introduction. In fact: while Zovirax Creme (Glaxo) DECLINED 4% for the first half of 2020; Lyranda® GREW 7.5% during the same period according to IMS data.
Our unique delivery system cuts cold sore healing time by more than 60%.
The global market is estimated at $52 bn with a compounded annual growth rate of 5.4%. Our patented strains absorb fatty acids besides metabolic effects, making them an innovative, natural solution for weight management. Our formulations have NO gastrointestinal side effects; NO steatorrhea (oily, loose stools), often seen with weight loss medication (Orlistat).
A 12 - week randomized, double-blind, placebo-control trial in obese adults (BMI 25-35) on a high-calorie diet and no change in exercise or lifestyle found: those taking a placebo gained 2.73 lbs while the group taking our patented strains weight remained stable. Our strains also showed an increase in muscle mass and a nearly 4% DECREASE in body fat (vs. 3.4% INCREASE in the placebo group).
herbals & supplements
The global market value is expected to undergo a modest increase over the coming years, climbing from $3.7 bn to $5.3 bn by 2031, at a compound annual growth rate of 3.6%. Our ingredients have been recognized by the American Academy of Neurology and incorporated into their Guidelines for migraine prevention.
Our proprietory herbal extract (Petadolex®) has shown a 71% response rate as published in Neurology.
The sleep aids market is reported to reach $91.5 bn by 2025, with a compounded annual growth rate of 6.3% during the next five years. Sleep aids consist of medications or herbs which allow a person to get rest.
Our proprietary combination of potent herbal extracts plays a crucial role in maintaining a healthy sleep cycle.